Antisense oligonucleotide therapeutics (ASOs) have realized tremendous success over the last twenty years in the management of previously untreatable diseases. Therapeutic ASOs and siRNA are typically very potent therapeutics that present significant challenges in their isolation and quantitation out of biological fluids and tissues. Two groundbreaking solutions from Phenomenex; Clarity OTX and Biozen Oligo have become the key in the development of analytical methods for oligonucleotide therapeutics.

Michael McGinley is the director of Phenomenex’s global application laboratories in charge of generating scientific content supporting the company’s product portfolios in the clinical, food, environmental, and biopharmaceutical industries. Over his 20 years at Phenomenex, Michael has served in various product development, marketing, and technical management roles. He managed the development and commercialization of numerous products including its award-winning Gemini and Clarity product lines. Before Phenomenex, Michael was at Amgen where he held several positions over a dozen year span, including Associate Scientist, Project Manager, and Laboratory Head. Michael received his degree in Biochemistry from the University of California at Berkeley and was one of the early proteomics innovators where he helped establish the pioneering program at Amgen. Michael is a recognized chromatography expert and long-serving member of the editorial advisory board of LC/GC magazine. His fields of expertise include HPLC method development, proteomics, oligonucleotide chemistry, and protein characterization with over a hundred publications in the respective fields.